All articles by

GSK receives EMA approval for new Tyverb® (lapatinib) indication in combination with trastuzumab for patients with relapsed HER2-positive, HR-negative metastatic breast cancer

The European Medicines Agency (EMA) has granted an update to the marketing authorisation for Tyverb® (lapatinib) to be used in combination with Herceptin® (trastuzumab). This combination is indicated for adult patients with breast cancer whose tumours overexpress HER2 (ErbB2) with hormone receptor-negative (HR-) metastatic disease that has progressed on prior trastuzumab therapy(ies) in combination with chemotherapy.1